Drug Utilization Study Evaluating Additional Risk Minimization Measures for Upadacitinib in the Treatment of Atopic Dermatitis in Europe

ENCePP Code of conduct

Yes

Data sources

• Data source(s):
  Sweden National Cancer Register / Cancerregistret

  Sweden National Prescribed Drugs Register / Läkemedelsregistret

  Danish registries (access/analysis)
• Data source(s), other:
  The Swedish National Patient register ; The Swedish Cause of Death Register; Swedish Medical Birth Register; SMINET;
• Data sources (types):
  Administrative healthcare records (e.g., claims)

  Disease registry

  Laboratory tests and analyses

  Population registry

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No